top of page
Asian Institute of Research, Journal Publication, Journal Academics, Education Journal, Asian Institute
Asian Institute of Research, Journal Publication, Journal Academics, Education Journal, Asian Institute

Journal of Health and Medical Sciences

ISSN 2622-7258

Screen Shot 2018-08-12 at 1.24.09 AM.png
Screen Shot 2018-08-12 at 1.24.02 AM.png
Screen Shot 2018-08-12 at 1.23.57 AM.png
Screen Shot 2018-08-12 at 1.23.52 AM.png
open access

Published: 13 January 2024

Comparison Between Valproic Acid and Levetiracetam to Cognitive Function in Idiopathic Generalized Epilepsy

Nur Yulikawaty Nasser, Audry Devisanty Wuysang, Abdul Muis, Isra Wahid, Muhammad Akbar, Muhammad Iqbal Basri

Hasanuddin University

journal of social and political sciences
pdf download

Download Full-Text Pdf



Pages: 14-24

Keywords: Cognitive, Valproic Acid, Levetiracetam, Idiopathic Generalized Epilepsy


Epilepsy affects cognition through several mechanisms in a complex relationship. Valproic acid (VPA) and levetiracetam (LEV) are widely used due to their good efficacy and tolerability profiles. However, VPA may cause impairment of spatial working memory. There has not been much explanation regarding the negative cognitive side effects of LEV, few research suggests that LEV may even have a stimulating effect on cognition. Evidence of the comparative effects of anti-epileptic drugs on cognitive function is still limited. Objective: To investigate the effects of VPA monotherapy and LEV monotherapy on idiopathic generalized epilepsy patients. Methods: This was a cross-sectional observational study of patients with IGE taking either VPA monotherapy (n=28) or LEV (n=25). All patients underwent cognitive function assessment using MoCA-Ina, CDT, TMT A and B. Results: There was a significant association between 64.3% of patients taking VPA having MoCA-Ina score <26 vs. only 12% in patients taking LEV (OR 13.2, 95% CI 3.150-56.309, p<0.001), 35.7% of patients taking VPA vs. 0% in patients taking LEV on TMT-A score (p<0,001), and 46.4% of patients taking VPA vs. 4% in patients taking LEV on TMT-B score (OR 20.80, 95% CI 2.462-175.696, p 0,001). Neither patients with VPA monotherapy nor LEV monotherapy was statistically significant in CDT score (57.1% vs 36%, OR 0.422, 95% CI 0.139-1.277, p 0.170). Conclusion: This study showed patients with VPA have lower cognitive function than LEV. Further studies on cognitive function in epilepsy are recommended to provide information to assist in efficient drug selection decision-making for patients.


  1. Aguilar-Navarro, S. G., Mimenza-Alvarado, A. J., Samudio-Cruz, M. A., Hernández-Contreras, F. J., Gutiérrez-Gutiérrez, L. A., Ramírez-González, F., & Avila-Funes, J. A. (2018). Validation of the Clock Drawing Test Scoring Method in older adults with neurocognitive disorder. Salud Mental, 41(4), 179-186. doi:

  2. Aninditha, T., Harris, S., Wiratman, W. (2022). Handbook of Neurology Second Edition. Volume 1 (Buku Ajar Neurologi Edisi Kedua. Volume 1). Department of Neurology, University of Indonesia

  3. Asnakew, S., Legas, G., Belete, A., Admasu, F. T., Yitbarek, G. Y., Aytenew, T. M., Demise, B., Alemu, E. M., Alemu, M. A., Bayih, W. A., Feleke, D. G., Chanie, E. S., Birhane, B. M., & Kefale, D. (2022). Cognitive adverse effects of epilepsy and its predictors attending outpatient department of South Gondar zone hospitals, Amhara Region, Ethiopia 2020 /2021. PloS one, 17(12), e0278908.

  4. Claudya, A., Harahap, H. S., Amalia, E., & Indrayana, Y. (2018). Comparison of Clock Drawing Test Results of Epilepsy Patients with Carbamazepine and Phenytoin Therapy at Mutiara Sukma Mental Hospital (Perbandingan Hasil Clock Drawing Test Pasien Epilepsi dengan Terapi Karbamazepin dan Fenitoin di Rumah Sakit Jiwa Mutiara Sukma). Cermin Dunia Kedokteran (Cermin Dunia Kedokteran), 45(5), 327–330.

  5. Du, M., Andersen, S. L., Cosentino, S., Boudreau, R. M., Perls, T. T., & Sebastiani, P. (2022). Digitally generated Trail Making Test data: Analysis using hidden Markov modeling. Alzheimer's & dementia (Amsterdam, Netherlands), 14(1), e12292.

  6. El Sabaa, R. M., Hamdi, E., Hamdy, N. A., & Sarhan, H. A. (2020). Effects of Levetiracetam Compared to Valproate on Cognitive Functions of Patients with Epilepsy. Neuropsychiatric disease and treatment, 16, 1945–1953.

  7. Fellows, R. P., Dahmen, J., Cook, D., & Schmitter-Edgecombe, M. (2017). Multicomponent analysis of a digital Trail Making Test. The Clinical Neuropsychologist, 31(1), 154–167.

  8. Foster, E., Malpas, C. B., Ye, K., Johnstone, B., Carney, P. W., Velakoulis, D., O'Brien, T. J., & Kwan, P. (2020). Antiepileptic drugs are not independently associated with cognitive dysfunction. Neurology, 94(10), e1051–e1061.

  9. Harahap, H. S., Rizki, M., & Irawati, D. (2022). Factors associated with global cognitive impairment in epilepsy patients: a cross-sectional study in Mataram, Indonesia. Medical Journal of Indonesia, 31(3), 155-9.

  10. Hasegawa, N., & Annaka, H. (2022). Cognitive features of adult focal epilepsy with unknown etiology revealed by the trail making test. Epilepsy & behavior: E&B, 129, 108625.

  11. Hasegawa, N., & Annaka, H. (2023). Long-term effect associated with seizures and dynamic effect associated with treatment on cognitive dysfunction of adult patients with focal epilepsy as evaluated by the Trail Making Test. Epileptic disorders: international epilepsy journal with videotape, 25(5), 731–738.

  12. Khalife, M. R., Scott, R. C., & Hernan, A. E. (2022). Mechanisms for Cognitive Impairment in Epilepsy: Moving Beyond Seizures. Frontiers in neurology, 13, 878991.

  13. Khanna, S., Bala, S., Singh, Y., Sharma, T., Kalra, J., Dhasmana, D. C., & Kohli, S. (2019). Comparative evaluation of levetiracetam and valproic acid as monotherapy on cognitive impairment in patients of epilepsy. International Journal of Basic & Clinical Pharmacology, 8(4), 674–680.

  14. Koo, D. L., Hwang, K. J., Kim, D., Kim, Y. J., Kim, J. Y., Shin, W., Kim, M. R., Joo, E> Y., Lee, J. M., Hong, S. B., (2013). Effects of Levetiracetam Monotherapy on the Cognitive Function of Epilepsy Patients. Eur Neurol 70 (1-2): 88–94. doi:10.1159/000347230

  15. Kusumastuti, K., Gunadharma, S.m & Kustiowati, E. (2019). Epilepsy Management Guidelines, 6th Edition (Pedoman Tata Laksana Epilepsi, Edisi 6), pp 16. Airlangga University Press

  16. Liu, X. Y., Shi, T., Yin, W. N., Ren, Z. Y., Deng, Y. L., & Chen, S. D. (2016). Interictal epileptiform discharges were associated with poorer cognitive performance in adult epileptic patients. Epilepsy research, 128, 1–5.

  17. Lodhi, S., Agrawal, N. (2012). Neurocognitive problems in epilepsy. Advances in Psychiatric Treatment. 18(3):232-240. doi:10.1192/apt.bp.110.007930

  18. Mani, V., & Rashed Almutairi, S. (2023). Impact of levetiracetam on cognitive impairment, neuroinflammation, oxidative stress, and neuronal apoptosis caused by lipopolysaccharides in rats. Saudi Pharmaceutical Journal: SPJ: the official publication of the Saudi Pharmaceutical Society, 31(9), 101728.

  19. Miller, L. A., Galioto, R., Tremont, G., Davis, J., Bryant, K., Roth, J., LaFrance, W. C., Jr, & Blum, A. S. (2016). Cognitive impairment in older adults with epilepsy: Characterization and risk factor analysis. Epilepsy & behavior: E&B, 56, 113–117.

  20. Njamnshi, A. K., Chokote, E., Ngarka, L., Nfor, L. N., Tabah, E. N., Atchou, J. G. B, Angwafor, S. A.,  Nkouonlack, C., Mengnjo, M. K., Njamnshi, W. Y., Dema, F., Tatah, G. Y., Zoung-KanyiBissek, A., Annoni, J., Ruffieux, N. (2020). “Epilepsy-associated neurocognitive disorders (EAND) in an onchocerciasis-endemic rural community in Cameroon: A population-based case-control study.” Epilepsy & behavior: E&B vol. 112, 107437. doi:10.1016/j.yebeh.2020.107437

  21. Novak, A., Vizjak, K., & Rakusa, M. (2022). Cognitive Impairment in People with Epilepsy. Journal of Clinical Medicine, 11(1), 267.

  22. Pannangrong, W., Sirichoat, A., Wongsiri, T., Wigmore, P., & Welbat, J. U. (2019). Valproic acid withdrawal ameliorates impairments of hippocampal-spatial working memory and neurogenesis. Journal of Zhejiang University. Science. B, 20(3), 253–263.

  23. Perkins, J. D., Abdelmoneim, M. S., Wilkins, S. S., Kamran, S., Mesraoua, B., Melikyan, G., Alrabi, A., El-Bardissy, A., Elalamy, O., & Al Hail, H. J. (2023). Dosage, time, and polytherapy dependent effects of different levetiracetam regimens on cognitive function. Epilepsy & behavior: E&B, 148, 109453.

  24. Romoli, M., Mazzocchetti, P., D'Alonzo, R., Siliquini, S., Rinaldi, V. E., Verrotti, A., Calabresi, P., & Costa, C. (2019). Valproic Acid and Epilepsy: From Molecular Mechanisms to Clinical Evidences. Current neuropharmacology, 17(10), 926–946.

  25. Sanchez, P. E., Zhu, L., Verret, L., Vossel, K. A., Orr, A. G., Cirrito, J. R., Devidze, N., Ho, K., Yu, G. Q., Palop, J. J., & Mucke, L. (2012). Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proceedings of the National Academy of Sciences of the United States of America, 109(42), E2895–E2903.

  26. Sayed, N.M., Aldin, M.T.K., Ali, S.E., Hendy, H. E. (2023). Cognitive functions and epilepsy-related characteristics in patients with generalized tonic–clonic epilepsy: a cross-sectional study. Middle East Curr Psychiatry 30, 15 (2023).

  27. Shih, J. J., Tatum, W. O., & Rudzinski, L. A. (2013). New drug classes for the treatment of partial onset epilepsy: focus on perampanel. Therapeutics and clinical risk management, 9, 285–293.

  28. Szabo, K., Hennerici, M. G. (2014). Frontiers of Neurology and Neuroscience, The Hippocampus in Clinical Neuroscience Volume 34, () || Neuropsychological Measures of Hippocampal Function, (), 60–70. doi:10.1159/000356425

  29. Tedrus, G. M. A. S., Passos, M. L. G. A., Vargas, L. M., & Menezes, L. E. F. J. (2020). Cognition and epilepsy: Cognitive screening test. Dementia & neuropsychologia, 14(2), 186–193.

  30. Vossel, K., Ranasinghe, K. G., Beagle, A. J., La, A., Ah Pook, K., Castro, M., Mizuiri, D., Honma, S. M., Venkateswaran, N., Koestler, M., Zhang, W., Mucke, L., Howell, M. J., Possin, K. L., Kramer, J. H., Boxer, A. L., Miller, B. L., Nagarajan, S. S., & Kirsch, H. E. (2021). Effect of Levetiracetam on Cognition in Patients With Alzheimer Disease With and Without Epileptiform Activity: A Randomized Clinical Trial. JAMA neurology, 78(11), 1345–1354.

  31. Yaksa, B. K. K., Harahap, H. S., Amalia, E., & Indrayana, Y. (2018). The effect of the onset of seizure on clock drawing test score of epilepsy patients. Indonesian Journal of Medicine and Health (JKKI : Jurnal Kedokteran Dan Kesehatan Indonesia), 9(2), 95–101.

bottom of page